A clinical trail to study the effects of drug dexmedetomidine in cleft palate surgeries

A randomized controlled double blind trial to study the effects of dexmedetomidine in cleft palate surgeries - DEXCP

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2013/11/004165

Enrollment

Registered

2013-11-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PATIENTS HAVING CLEFT PALATE WHO ARE FIT FOR SURGERY

Interventions

Intervention1: DEXMEDETOMIDINE: 1 microgram per kg body weight to be given over 10 minutes IV as loading dose after induction followed by infusion at the rate of 0.5 microgram per kg body weight per

Eligibility

Inclusion criteria

Inclusion criteria: ASA I AGE 6 MONTHS TO 12 YEARS EITHER SEX

Exclusion criteria

Exclusion criteria: ASA II UNWILLING FOR CONSENT HISTORY SUGGESTIVE OF KIDNEY LIVE CARDIAC DYSFUNCTION ALLERGY TO ALPHA 2 ADRENERGIC AGONIST OR SULPHA DRUGS BRADYCARDIA HR < 60/MIN

Design outcomes

Primary

Measure	Time frame
HAEMODYNAMIC STABILITY ANALGESIC REQUIREMENT RECOVERY PROFILE SURGEON SATISFACTION SCORETimepoint: 2 years	—

Secondary

Measure	Time frame
EMERGENCE AGITATION POST OP SEDATION ANS ANALGESIC REQUIREMENTTimepoint: 2 YEARS	—

Countries

India

Contacts

Public ContactDr DEVANGI PARIKH

LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL

sdevangi10@gmail.com9820471638

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026